4.1 Article

The utility of silent myocardial infarction on electrocardiogram as an ASCVD risk enhancer for primary prevention: The multi-ethnic study of atherosclerosis

Journal

JOURNAL OF ELECTROCARDIOLOGY
Volume 65, Issue -, Pages 105-109

Publisher

CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
DOI: 10.1016/j.jelectrocard.2021.01.018

Keywords

Silent myocardial infarction; Atherosclerotic cardiovascular disease; Biomarkers; Cardiovascular risk

Funding

  1. National Heart, Lung, and Blood Institute [75N92020D00001, HHSN268201500003I, N01HC95159, 75N92020D00005, N01HC95160, 75N92020D00002, N01HC95161, 75N92020D00003, N01HC95162, 75N92020D00006, N01HC95163, 75N92020D00004, N01HC95164, 75N92020D00007, N01HC95165, N01HC95166, N01HC95167, N01-HC-95168, N01-HC-95169]
  2. National Center for Advancing Translational Sciences (NCATS) [UL1TR000040, UL1TR001079, UL1-TR-001420]

Ask authors/readers for more resources

The study evaluated the utility of SMI on ECG as a risk enhancer in intermediate-risk participants and found that while SMI was associated with an increased risk of incident ASCVD events, adding it to the PCE did not improve discrimination significantly. This suggests that SMI may not be very useful as an ASCVD risk enhancer.
Background: The 2018 AHA/ACC cholesterol guidelines introduced a new list of markers called risk enhancers that, if present, confer an increased risk of atherosclerotic cardiovascular disease (ASCVD). Silent myocardial infarction (SMI) on electrocardiogram (ECG) is notably absent, even though it associated with future ASCVD. Methods: We assessed the utility of SMI on ECG as a risk-enhancer in intermediate-risk participants in MESA (Multi-Ethnic Study of Atherosclerosis) - those with 10-year ASCVD risk of 5-20% by the pooled cohort equation (PCE). SMI was defined as major Q-wave abnormality or minor Q/QS waves in the setting of major ST-T abnormalities without prevalent clinical cardiovascular disease. Results: Among 2946 participants (mean age 63.1 +/- 7.6, 53.9% women, 36% white, 11% Chinese-American, 33% African-American, 19% Hispanic), 66 (2.2%) had SMI at baseline. After a median 15.8 years of follow-up, incident ASCVD events occurred in 431/2876 (15.0%) of those without SMI and 16/66 (24.2%) of those with SMI. In a multivariable-adjusted Cox proportional hazards model, baseline SMI was associated with an increased risk of incident ASCVD events (HR 1.68, 95% CI 1.02-2.77, p = 0.04). However, adding SMI to the PCE did not improve discrimination and reclassification was modest-net reclassification improvement was 0.0161 (95% CI 0.002-0.034, p = 0.08). Conclusion: Our findings suggest that the prevalence of SMI is 2.2% among those without known clinical cardiovascular disease considered intermediate-risk by the PCE. In our analysis, SMI only modestly improved classifica-tion of risk, suggesting that it may not be very useful as an ASCVD risk enhancer (c) 2021 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available